Breaking News, Collaborations & Alliances

AbelZeta, AstraZeneca Partner on Novel GPC3 Armored CAR-T Therapy

AbelZeta will receive an upfront payment from AstraZeneca for the co-development and commercialization of C-CAR031 in China.

AbelZeta Pharma Inc., a global clinical-stage biopharmaceutical company focused on innovative cell therapies for cancer, inflammatory and immunological diseases, entered into an agreement with AstraZeneca to co-develop C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T Cells (CAR-T) therapy, in hepatocellular carcinoma (HCC). C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II (TGF...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters